B+
Bull case
20%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
ZURA
Zura BioCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Positive TibuSHIELD data could substantially revalue tibulizumab ahead of the later systemic sclerosis readout. Zura reported $205.1 million of cash at June 30, 2026 and expects funding for planned operations through at least 2028.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +17.5.
What can break
Launching NEXUS-PMR may increase R&D spending; the stated runway is a company estimate contingent on planned operations. [#SEC-8K-2026-08-11]
Momentum
12
Value
41
Sentiment
73
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.00 · Bull $8.00 · Bear $1.50Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $18.83
Why
Momentum12 · Δ7d +3.4
Value41 · Δ7d -0.1
Sentiment73 · Δ7d +17.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +17.5.
Contradictions & invalidation
- • Launching NEXUS-PMR may increase R&D spending; the stated runway is a company estimate contingent on planned operations. [#SEC-8K-2026-08-11]
- • Low coverage, loose peer comparability, and unverified analyst-target breadth constrain valuation confidence.
- • An inconclusive or negative Phase 2 result could impair the lead-program thesis; additional studies could raise spending despite the stated runway.
Catalyst clock
2026-12-31
TibuSHIELD Phase 2 hidradenitis suppurativa readout
Lead driver: Sentiment · See AI snapshot
Momentum
12
8% active weight
Current posture
7d trendSoftening
Δ7d
+3.4
Δ21d
+2.0
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
73
45% active weight
Current posture
7d trendImproving
Δ7d
+17.5
Δ21d
+17.1
Why this grade
Composite grade C. Momentum 12.3 / Value 40.6 / Sentiment 73.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$4.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$321.99M
Beta
0.21
Shares Out
95.83M
P/E (TTM) · Derived
-3.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.20
Rev YoY
-
EPS YoY
+22.3%
Gross Margin
-
Op Margin
-
Net Debt
-$109.41M
Current Ratio
12.90
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data